Healthcare Costs of Acute and Chronic Pain Associated with a Diagnosis of Herpes Zoster
dc.contributor.author | Dworkin, Robert H. | en_US |
dc.contributor.author | White, Richard | en_US |
dc.contributor.author | O'Connor, Alec B. | en_US |
dc.contributor.author | Baser, Onur | en_US |
dc.contributor.author | Hawkins, Kevin | en_US |
dc.date.accessioned | 2010-04-01T15:51:14Z | |
dc.date.available | 2010-04-01T15:51:14Z | |
dc.date.issued | 2007-08 | en_US |
dc.identifier.citation | Dworkin, Robert H.; White, Richard; O'Connor, Alec B.; Baser, Onur; Hawkins, Kevin (2007). "Healthcare Costs of Acute and Chronic Pain Associated with a Diagnosis of Herpes Zoster." Journal of the American Geriatrics Society 55(8): 1168-1175. <http://hdl.handle.net/2027.42/66349> | en_US |
dc.identifier.issn | 0002-8614 | en_US |
dc.identifier.issn | 1532-5415 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/66349 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17661954&dopt=citation | en_US |
dc.description.abstract | To determine the healthcare costs of acute and chronic pain associated with herpes zoster. DESIGN : Retrospective cohort analysis. SETTING : Inpatient and outpatient care. PARTICIPANTS : Patients were selected from Medicare, commercial insurance, and Medicaid claims databases if they had a diagnosis of herpes zoster or postherpetic neuralgia (PHN) or were prescribed analgesics after a diagnosis of herpes zoster (possible PHN) and were matched to controls for demographic and clinical factors using propensity scores. MEASUREMENTS : One-year excess healthcare expenditures attributable to herpes zoster pain or PHN were calculated for inpatient, outpatient, and prescription drug services. RESULTS : For the Medicare cohort, the average excess cost per patient was $1,300 in the year after a diagnosis of herpes zoster with 30 days or fewer of analgesic use and ranged from $2,200 to $2,300 per patient with PHN or possible PHN. Patients with possible PHN were 53% more prevalent than patients with PHN in the Medicare cohort and accounted for half of all excess expenditures. Findings were similar in the younger cohorts with commercial insurance and Medicaid except that costs attributable to PHN and possible PHN were higher, and patients with possible PHN were three to five times as prevalent as patients with PHN. CONCLUSION : Healthcare costs associated with PHN were substantially greater than those associated with herpes zoster pain that resolved within 30 days. The data suggest that as many as 80% of patients with PHN may not be diagnosed with PHN and that these patients account for at least half of PHN expenditures. | en_US |
dc.format.extent | 119375 bytes | |
dc.format.extent | 3110 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Publishing Inc | en_US |
dc.rights | © 2007, The American Geriatrics Society | en_US |
dc.subject.other | Herpes Zoster | en_US |
dc.subject.other | Postherpetic Neuralgia | en_US |
dc.subject.other | Acute Pain | en_US |
dc.subject.other | Chronic Pain | en_US |
dc.subject.other | Healthcare Costs | en_US |
dc.title | Healthcare Costs of Acute and Chronic Pain Associated with a Diagnosis of Herpes Zoster | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Geriatrics | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Thomson-Medstat, Ann Arbor, Michigan ; and | en_US |
dc.contributor.affiliationum | IMS Health, Ann Arbor, Michigan. | en_US |
dc.contributor.affiliationother | Anesthesiology , | en_US |
dc.contributor.affiliationother | Neurology , | en_US |
dc.contributor.affiliationother | Medicine, School of Medicine and Dentistry, University of Rochester, Rochester, New York ; | en_US |
dc.contributor.affiliationother | Endo Pharmaceuticals, Chadds Ford, Pennsylvania ; | en_US |
dc.identifier.pmid | 17661954 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/66349/1/j.1532-5415.2007.01231.x.pdf | |
dc.identifier.doi | 10.1111/j.1532-5415.2007.01231.x | en_US |
dc.identifier.source | Journal of the American Geriatrics Society | en_US |
dc.identifier.citedreference | Hope-Simpson RE. The nature of herpes zoster : A long-term study and a new hypothesis. Proc R Soc Med 1965 ; 58 : 9 – 20. | en_US |
dc.identifier.citedreference | Gnann JW Jr, Whitley RJ. Herpes zoster. N Engl J Med 2002 ; 347 : 340 – 346. | en_US |
dc.identifier.citedreference | Hope-Simpson RE. Postherpetic neuralgia. J R Coll Gen Pract 1975 ; 25 : 571 – 575. | en_US |
dc.identifier.citedreference | Donohue JG, Choo PW, Manson JE et al. The incidence of herpes zoster. Arch Intern Med 1995 ; 155 : 1605 – 1609. | en_US |
dc.identifier.citedreference | Brisson M, Edmunds WJ, Law B et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect 2001 ; 127 : 305 – 314. | en_US |
dc.identifier.citedreference | Brisson M, Edmunds WJ. Epidemiology of varicella-zoster virus in England and Wales. J Med Virol 2003 ; 70 : S9 – S14. | en_US |
dc.identifier.citedreference | Chapman RS, Cross KW, Fleming DM. The incidence of shingles and its implications for vaccination policy. Vaccine 2003 ; 21 : 2541 – 2547. | en_US |
dc.identifier.citedreference | Oxman MN, Levin MJ, Johnson GR et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005 ; 352 : 2271 – 2284. | en_US |
dc.identifier.citedreference | Scott FT, Leedham-Green ME, Barret-Muir WY et al. A study of shingles and the development of postherpetic neuralgia in east London. J Med Virol 2003 ; 70 ( Suppl 1 ) : S24 – S30. | en_US |
dc.identifier.citedreference | Arani RB, Soong SJ, Weiss HL et al. Phase specific analysis of herpes zoster associated pain data : A new statistical approach. Stat Med 2001 ; 20 : 2429 – 2439. | en_US |
dc.identifier.citedreference | Desmond RA, Weiss HL, Arani RB et al. Clinical application for change-point analysis of herpes zoster pain. J Pain Symptom Manage 2002 ; 23 : 510 – 516. | en_US |
dc.identifier.citedreference | Jung BF, Johnson RW, Griffin DRJ et al. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology 2004 ; 62 : 1545 – 1551. | en_US |
dc.identifier.citedreference | Bennett GJ. Neuropathic pain : An overview. In : Borsook D, ed. Molecular Neurobiology of Pain. Seattle : IASP Press, 1997, pp 109 – 113. | en_US |
dc.identifier.citedreference | Bowsher D. The lifetime occurrence of herpes zoster and prevalence of postherpetic neuralgia : A retrospective survey in an elderly population. Eur J Pain 1999 ; 3 : 335 – 342. | en_US |
dc.identifier.citedreference | Dworkin RH, White R, O'Connor AB et al. Health care expenditure burden of persisting herpes zoster pain. Pain Med ; in press. | en_US |
dc.identifier.citedreference | Cepeda MS, Farrar JT. Economic evaluation of oral treatments for neuropathic pain. J Pain 2006 ; 7 : 119 – 128. | en_US |
dc.identifier.citedreference | Hornburger J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med 2006 ; 145 : 317 – 325. | en_US |
dc.identifier.citedreference | Dworkin RH, Backonja M, Rowbotham MC et al. Advances in neuropathic pain : Diagnosis, mechanisms, and treatment recommendations. Arch Neurol 2003 ; 60 : 1524 – 1534. | en_US |
dc.identifier.citedreference | Oster G, Berger A, Dukes E et al. Use of potentially inappropriate pain-related medications in older adults with painful neuropathic disorders. Am J Geriatr Pharmacother 2004 ; 2 : 163 – 170. | en_US |
dc.identifier.citedreference | Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies : Development and validation. J Chronic Dis 1987 ; 40 : 373 – 383. | en_US |
dc.identifier.citedreference | D'Hoore W, Bouckaert A, Tilquin C. Practical considerations on the use of the Charlson comorbidity index with administrative data bases. J Clin Epidemiol 1996 ; 49 : 1429 – 1433. | en_US |
dc.identifier.citedreference | Ashcraft ML, Fries BE, Nerenz DR et al. A psychiatric patient classification system : An alternative to diagnosis-related groups. Med Care 1989 ; 27 : 543 – 557. | en_US |
dc.identifier.citedreference | Basur O. Too much ado about propensity score models? Comparing methods of propensity score matching. Value Health 2006 ; 9 : 377 – 385. | en_US |
dc.identifier.citedreference | Ganguly R, Martin B, Dorfman J et al. In search of an unbiased estimate of treatment effect using observational data : A comparison of propensity scoring and Heckman two stage sample selection models. ISPOR Connections 2004 ; 10 : 2 – 5. | en_US |
dc.identifier.citedreference | Ozminkowski RJ, Burton W, Goetzel R et al. The impact of rheumatoid arthritis on medical expenditures, absenteeism, and short-term disability benefits. J Occup Environ Med 2006 ; 48 : 135 – 148. | en_US |
dc.identifier.citedreference | Davies L, Cossins L, Bowsher D et al. The cost of treatment for post-herpetic neuralgia in the UK. Pharmacoeconomics 1994 ; 6 : 142 – 148. | en_US |
dc.identifier.citedreference | Dworkin RH, Schmader KE. Epidemiology and natural history of herpes zoster and postherpetic neuralgia. In : Watson CPN, Gershon AA, eds. Herpes Zoster and Postherpetic Neuralgia, 2nd Ed. New York : Elsevier Press, 2001, pp 39 – 64. | en_US |
dc.identifier.citedreference | Coplan PM, Schmader K, Nikas A et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials : Adaptation of the Brief Pain Inventory. J Pain 2004 ; 5 : 344 – 356. | en_US |
dc.identifier.citedreference | Lydick E, Epstein R, Himmelberger D et al. Herpes zoster and quality of life : A self-limited disease with severe impact. Neurology 1995 ; 45 ( Suppl 8 ) : S52 – S53. | en_US |
dc.identifier.citedreference | Katz J, Cooper EM, Walther RR et al. Acute pain in herpes zoster and its impact on health-related quality of life. Clin Infect Dis 2004 ; 39 : 342 – 348. | en_US |
dc.identifier.citedreference | Brisson M, Edmunds WJ. Varicella vaccination in England and Wales : Cost-utility analysis. Arch Dis Child 2003 ; 88 : 862 – 869. | en_US |
dc.identifier.citedreference | Paul JE, Mauskopf JA, Bell L. Cost-consequence models for varicella-zoster virus infections. Pharmacotherapy 1995 ; 15 : 49S – 58S. | en_US |
dc.identifier.citedreference | GrÜger J, Backhouse ME. Economic evaluation of antiviral therapy for the treatment of herpes zoster in immunocompetent adults. Pharmacoeconomics 1997 ; 11 : 262 – 273. | en_US |
dc.identifier.citedreference | Huse DM, Schainbaum S, Kirsch AJ et al. Economic evaluation of famciclovir in reducing the duration of postherpetic neuralgia. Am J Health Syst Pharmacol 1997 ; 54 : 1180 – 1184. | en_US |
dc.identifier.citedreference | Smith KJ, Roberts MS. Cost effectiveness of newer antiviral agents for herpes zoster : Is the evidence spotty? J Infect Dis 1998 ; 178 ( Suppl 1 ) : S85 – S90. | en_US |
dc.identifier.citedreference | Berger A, Dukes EM, Oster G. Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain 2004 ; 5 : 143 – 149. | en_US |
dc.identifier.citedreference | Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis 2004 ; 4 : 26 – 33. | en_US |
dc.identifier.citedreference | Mullooly JP, Riedlinger K, Chun C et al. Incidence of herpes zoster, 1997–2002. Epidemiol Infect 2005 ; 133 : 245 – 253. | en_US |
dc.identifier.citedreference | Yih WK, Brooks DR, Lett SM et al. The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998–2003. BMC Public Health 2005 ; 5. | en_US |
dc.identifier.citedreference | Schuette MC, Hethcote HW. Modeling the effects of varicella vaccination programs on the incidence of chickenpox and shingles. Bull Math Biol 1999 ; 61 : 1031 – 1064. | en_US |
dc.identifier.citedreference | Edmunds WJ, Brisson M. The effect of vaccination on the epidemiology of varicella zoster virus. J Infect 2002 ; 44 : 211 – 219. | en_US |
dc.identifier.citedreference | Brisson M, Edmunds WJ, Gay NJ. Varicella vaccination : Impact of vaccine efficacy on the epidemiology of VZV. J Med Virol 2003 ; 70 : S31 – S37. | en_US |
dc.identifier.citedreference | Grant DM, Mauskopf JA, Bell L et al. Comparison of valaciclovir and acyclovir for the treatment of herpes zoster in immunocompetent patients over 50 years of age : A cost-consequence model. Pharmacotherapy 1997 ; 17 : 333 – 341. | en_US |
dc.identifier.citedreference | Hempenstall K, Nurmikko TJ, Johnson RW et al. Analgesic therapy in postherpetic neuralgia : A quantitative systematic review. PLoS Med 2005 ; 2 : 0628 – 0644. | en_US |
dc.identifier.citedreference | Watson CPN. Postherpetic neuralgia : The importance of preventing this intractable end-stage disorder. J Infect Dis 1998 ; 178 ( Suppl 1 ) : S91 – S94. | en_US |
dc.identifier.citedreference | Smith KJ, Roberts MS. Antiviral therapies for herpes zoster infections : Are they economically justifiable? Pharmacoeconomics 2000 ; 2 : 95 – 104. | en_US |
dc.identifier.citedreference | Dworkin RH, Johnson RW, Breuer J et al. Recommendations for the management of herpes zoster. Clin Infect Dis 2007 ; 44 ( Suppl 1 ) : S1 – S26. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.